NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Biomerica, Inc. (BMRA) Stock Analysis

Biomerica, Inc. (BMRA) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

BMRA

$2.31

+$0.09 (+4.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BMRA with… →

BMRA Key Statistics

As of Sep 4, 2026
Trading
Open
$2.27
Previous Close
$2.22
Day's Range
2.21–2.35
52-Week Range
1.45–3.21
Volume
54.40K
Valuation
Market Cap
$10.60M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
5.92
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.38
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.34
Financials (FY)
Revenue (FY)
$5.31M−1.92%
Net Income (FY)
−$4.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
−84.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.59M
1-Year Return
−18.09%
Dividend and dates
Avg Volume
67.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BMRA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.33%
2025+5.00%
2024−76.00%
2023−62.69%
2022−13.88%
2021−21.89%
2020+64.90%
2019+77.65%
2018−54.55%
2017+62.61%
2016 (partial year)−12.55%

As of September 4, 2026.

BMRA Revenue and Earnings by Fiscal Year

FY ends May
Fiscal yearRevenueNet incomeNet margin
2024$5.31M−$4.97M−93.6%
2023$5.42M−$5.98M−110.4%
2022$5.34M−$7.14M−133.7%
2021$18.87M−$4.53M−24.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$5.31M$498.00K−$5.14M−$4.97M−93.6%
2023$5.42M$611.00K−$6.37M−$5.98M−110.4%
2022$5.34M$446.00K−$7.22M−$7.14M−133.7%
2021$18.87M$2.98M−$4.53M−$4.53M−24.0%

Annual figures as reported, in the company's reporting currency. As of May 31, 2025.

BMRA Valuation vs Medical Devices Median

Median of 151 stocks
MetricBMRAMedical Devices medianvs median
P/S ratio2.382.9820% below
Profit margin−84.77%−1.69%83.1 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Biomerica, Inc. (BMRA) is capitalised at $10.60M on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry.

The 52-week range on file runs from $1.45 to $3.21. The most recent close on file for BMRA is $2.31, dated September 4, 2026. That is +$0.09 (+4.05%) against the previous close. The latest close sits 59.31% above that 52-week low.

Financial Health

Fiscal 2024 revenue came to $5.31M. Against the prior fiscal year total of $5.42M, that is a change of −1.92%. The same year closed with a net loss of $4.97M. The reported profit margin is −84.77%. That is 83.1 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −1.34.

Across the 4 fiscal years on file, revenue moves from $18.87M in 2021 to $5.31M in 2024. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 5.92. The price-to-sales ratio is 2.38. On price-to-sales that is 20.01% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Daily returns over the trailing 10 years annualize to a volatility of 139.75%. The trailing one-year price return is −18.09%. Across 10 years the annualized return works out at −20.29%.

Growth & Income

No dividend is on file for BMRA.

Across the complete calendar years on file, 2019 returned +77.65% and 2024 returned −76.00%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is −8.33%.

Peer Comparison

Biomerica, Inc. (BMRA) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biomerica, Inc. BMRA $10.60M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Biomerica, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Biomerica, Inc.

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Visit website →